Microbot Medical (NASDAQ:MBOT – Get Free Report) had its price objective decreased by investment analysts at B. Riley Financial from $4.00 to $3.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. B. Riley Financial‘s target price would indicate a potential upside of 316.09% from the company’s previous close.
Several other equities analysts have also recently issued reports on the company. Wall Street Zen cut Microbot Medical from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 24th. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Microbot Medical in a research note on Wednesday, October 21st. UBS Group set a $2.50 price target on Microbot Medical in a report on Friday, October 23rd. Weiss Ratings downgraded Microbot Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Microbot Medical in a report on Tuesday. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $4.83.
View Our Latest Research Report on MBOT
Microbot Medical Stock Performance
NASDAQ MBOT traded down $0.00 during trading on Thursday, reaching $0.72. 254,434 shares of the company’s stock were exchanged, compared to its average volume of 1,335,497. The stock has a market cap of $48.43 million, a P/E ratio of -2.77 and a beta of 1.07. The company has a 50 day moving average price of $1.12 and a two-hundred day moving average price of $1.78. Microbot Medical has a 1 year low of $0.52 and a 1 year high of $2.85.
Microbot Medical (NASDAQ:MBOT – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.01 million. Research analysts forecast that Microbot Medical will post -0.30 EPS for the current fiscal year.
Institutional Trading of Microbot Medical
Large investors have recently bought and sold shares of the company. CTC Alternative Strategies Ltd. acquired a new position in shares of Microbot Medical during the 1st quarter worth $28,000. Cetera Investment Advisers grew its stake in Microbot Medical by 44.7% in the 1st quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 13,099 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in Microbot Medical by 1,688.1% in the 1st quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 71,560 shares during the last quarter. Institutional investors and hedge funds own 16.30% of the company’s stock.
Microbot Medical Company Profile
Microbot Medical is a medical-device company developing robotic technologies for endovascular procedures. Its work focuses on tools intended to help physicians navigate blood vessels and perform minimally invasive interventions. The company’s lead platform, LIBERTY, is a remotely operated robotic system designed for endovascular procedures. The system is intended to work with guidewires and catheters and to support physicians in controlling these devices during treatment. Microbot Medical is based in the United States and has roots in Israel.
See Also
- Five stocks we like better than Microbot Medical
- 3 Niche ETFs Are Beating the S&P 500, and Their Strategies Are Anything but Typical
- The Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.
